Articles tagged with Radiation Therapy
A phase III trial comparing proton and photon radiation therapy for breast cancer found that patients report equally strong health-related quality of life with either treatment. Patients treated with protons were more likely to say they would recommend or choose it again, but overall patient-reported outcomes were similar.
A phase III trial suggests that post-operative radiation therapy can reduce cancer recurrence in patients with high-risk disease. Patients who received radiation experienced significantly fewer pelvic recurrences and improved locoregional recurrence-free survival compared to those who did not receive radiation.
A retrospective study found that radiation therapy controlled ventricular tachycardia with fewer complications than standard catheter ablation. Radiation therapy was similarly effective in controlling arrhythmia and showed lower serious side effects, especially in the early time window.
A new clinical trial found that patients with mild-to-moderate knee osteoarthritis reported significant reductions in pain and improved physical function after receiving low-dose radiation therapy. The study showed a 70% response rate in the high-dose group, compared to 42% in the placebo group.
A new randomized study validates a predictive gene expression test that identifies patients with recurrent prostate cancer who will benefit from adding hormone therapy to radiation. The test, PAM50, groups tumors into molecular subtypes and predicts treatment outcomes.
A new PSMA-targeting radioligand therapy added to stereotactic body radiotherapy (SBRT) more than doubled progression-free survival in men with recurrent prostate cancer, delaying the start of hormone therapy by up to 24 months. The study found minimal side effects and identified biological markers that may predict treatment benefits.
A new clinical trial found that adding a PSMA-targeting agent to stereotactic radiation therapy doubled progression-free survival in patients with limited metastatic prostate cancer. The study also showed that the treatment delayed hormone therapy by 24 months and improved local control.
Researchers found that SBRT and surgery had similar 10-year outcomes for patients with early-stage non-small cell lung cancer, with radiation offering quality-of-life benefits. The study also showed a higher acute complication rate caused by surgery.
Researchers from UCLA presented findings on targeted radioactive therapy, new SBRT approaches and advances in MRI- and 5DCT-guided imaging. The LUNAR clinical trial looked at adding a targeted therapy before ablative radiotherapy for men with recurrent prostate cancer.
Researchers developed a genomic model to tailor radiation doses to individual patients with HPV-positive throat cancer. The study found that higher scores on the Genomic Adjusted Radiation Dose (GARD) model were associated with improved survival outcomes, even when patients received the same radiation dose.
The American Society for Radiation Oncology, American Society of Clinical Oncology, and Society of Surgical Oncology jointly published a guideline outlining when post-mastectomy radiation therapy (PMRT) is appropriate based on new evidence. PMRT reduces cancer recurrence risk in patients with node-positive disease or high-risk features.
Researchers have developed a new technique to measure boron in individual cancer cells, enabling the study of how drugs interact with tumour cells. This breakthrough could lead to more effective treatments for head and neck cancers.
Researchers at MD Anderson have made significant advancements in treating kidney cancer, including the use of metastasis-directed targeted radiation therapy to delay systemic treatments. Additionally, preliminary data from an ELI-002 vaccine trial showed promise in delaying relapse of KRAS-mutated pancreatic and colorectal cancers.
A Mayo Clinic study shows that a shorter, less intense course of radiation and chemotherapy after minimally invasive surgery significantly reduces treatment-related side effects while maintaining high cure rates. The findings apply to intermediate-risk patients, with slightly better disease control in high-risk patients.
Researchers developed CerviPro, a multimodal deep learning model that accurately identifies high-risk patients with locally advanced disease. The model achieved superior predictive performance compared to conventional methods and provided critical prognostic insights.
Researchers at the University of Navarra have developed FLIP-HEDOS, a model that simulates how much radiation blood absorbs during cancer treatment. The study highlights the importance of protecting blood from radiation, which can impair immune function and lead to hematologic toxicity.
Researchers successfully treat mouse tumor with radioactive carbon ion beam, achieving complete control without major neurological side effects. The BARB project advances image-guided particle therapy using exotic beams, showing feasibility and effectiveness.
The Huntsman Cancer Institute is launching new clinical trials to explore how theranostics can help more patients. Theranostics combines diagnostics and therapeutics to deliver targeted radiation directly to cancer cells, offering a powerful approach to finding and treating cancer.
The researchers developed a novel approach to virtual contrast enhancement in MRI imaging, using pixelwise gradient methods with Generative Adversarial Networks. The model excelled in capturing intricate details and textures, outperforming its predecessor in texture representation.
This book presents cutting-edge approaches to combat cancer, including exosomal delivery systems, CRISPR/Cas9 gene editing, and immunotoxin therapy. Natural compounds are also examined for their anticancer potential.
A study documents elite-level strength training during active breast cancer treatment, showing rare retention of squat strength despite chemotherapy. LaShae Rolle, a competitive powerlifter and breast cancer survivor, completed the first-of-its-kind study, demonstrating the feasibility of high-intensity training when carefully managed.
Researchers have discovered a key role of centrosomes in signaling cells to proliferate despite DNA damage, enabling cancer resistance. The study suggests targeting Polo-like kinase 1 could prevent adaptation to therapy-induced DNA damage and drug resistance.
A new treatment approach using cyclophosphamide has been found to prevent most graft-versus-host disease in mismatched transplants. The study shows that 80% of patients are alive after a year, similar to outcomes seen in fully matched transplants.
Researchers at Mass General Brigham found that targeted radiation was successful in treating patients with brain metastases, resulting in a lower neurological death rate and reduced need for subsequent whole brain radiation. This study supports personalized treatment approaches to maintain quality of life while managing brain metastases.
Researchers at Fujita Health University discovered benzaldehyde's mechanism to halt therapy-resistant pancreatic cancer growth and spread. Benzaldehyde prevents key interactions that enable cancer cells' survival and treatment resistance.
A new AI tool, iSeg, has been developed to accurately outline lung tumors on CT scans and identify areas that may be missed by doctors. The study found that iSeg consistently matched expert outlines across hospitals and scan types, and flagged additional areas that some doctors missed.
The American Society for Radiation Oncology (ASTRO) has updated its guideline on radiation therapy for high-grade diffuse gliomas, the most common primary brain tumor in adults. The new guideline provides evidence-based recommendations for multidisciplinary treatment and addresses optimal radiation dosing, fractionation, and techniques.
Researchers at MD Anderson have made significant breakthroughs in cancer treatment, including improved outcomes for elderly patients with IDH-mutant AML who are not eligible for intensive chemotherapy. Additionally, new targeted therapies have been approved as frontline treatments, while pre-surgical radiation therapy may offer an alte...
Mayo Clinic has opened its first carbon ion therapy program in the Western Hemisphere, providing new hope for patients with treatment-resistant cancers. The Duan Family Building will also offer advanced proton therapy and other cancer treatments.
The CompassHER2 trial found that neoadjuvant THP led to a pathologic complete response (pCR) rate of 64% in patients with early-stage HER2-positive, ER-negative breast cancer. Lower ER expression levels resulted in higher pCR rates among ER-positive tumors.
Researchers found that stereotactic body radiotherapy (SBRT) is as safe as conventional treatment, with similar side effects and quality of life. SBRT shortens treatment time and may have biological advantages in targeting prostate cancer.
A new clinical trial has shown that a lower dose of radiotherapy can lead to higher levels of complete disappearance of cancer and fewer short-term side effects. The treatment approach, led by Professor David Sebag-Montefiore, aims to reduce the burden on patients and healthcare systems.
The American Society for Radiation Oncology (ASTRO) will host its 67th Annual Meeting in San Francisco from September 27 to October 1, 2025. The meeting will feature over 2,500 research presentations and posters on advances in radiation oncology and non-cancer indications.
Researchers at the University of Chicago Medicine discovered a new phenomenon where high doses of radiation cause growth in existing metastatic tumors. The 'badscopal effect' is attributed to increased production of amphiregulin, which weakens the immune system and makes cancer cells more resistant.
Researchers have identified conditions under which ultra-high dose rate carbon ion beams can spare normal cells while maintaining tumor control, opening new possibilities for safer radiotherapy. The study reveals a cell-sparing effect under normoxic conditions using higher linear energy transfer values.
The University of Texas at Arlington's nursing and physics team has developed a system to study alpha radiation, improving the effectiveness of radiation therapy. The team's research was recognized with the Best in Physics award at the American Association of Physicists in Medicine's annual meeting.
A 10-year study confirms a one-week course of post-surgery radiotherapy is just as safe and effective as the traditional three-week regimen for early-stage breast cancer patients. This shorter schedule provides similar cancer control without additional long-term side effects.
A Phase III trial shows molecular profiling can safely reduce radiation for women with early-stage endometrial cancer, tailoring treatment to individual tumour characteristics. Nearly half of patients can be spared radiotherapy without compromising cancer control.
New studies showcase radiotherapy's potential as a curative treatment for rectal cancer, offering safer alternatives to surgery. Reduced-dose treatments and immunotherapy-combined regimens have improved tumour control and reduced side effects.
A phase III clinical trial has shown that a two-and-a-half week course of precision radiotherapy is equally successful in beating prostate cancer as the standard eight-week approach. After 10 years, both options produced similar disease control rates and survival rates.
A study found that most head-and-neck cancer survivors who underwent radiation don't know about survivorship care, despite grapple with side effects such as dry mouth, swallowing problems, and psychological distress. The survey also found that 40% of survivors still struggle with dry mouth and nearly a quarter reported trouble swallowing.
Researchers at TUM developed an AI-powered algorithm to predict kidney damage in prostate cancer patients undergoing lutetium-177 PSMA therapy. Early detection could enable personalized treatment adjustments to prevent organ damage.
Researchers from the University of Cincinnati Cancer Center presented abstracts highlighting contrasting effects of a protein on head and neck, breast, and lung cancers. The study found increased levels of IL-9 in patients with head and neck cancer correlated with decreased survival, while elevated IL-9 was associated with smaller tumo...
A patient with adenoid cystic carcinoma was successfully treated with step-and-shoot proton arc therapy at Corewell Health William Beaumont University Hospital. The treatment showed minimal side effects, including only light skin discoloration, and the patient remains cancer-free.
Hyperbaric oxygen treatment has been shown to provide long-term relief for patients with late radiation-induced injuries, improving symptoms of urinary incontinence, bleeding, and severe pain. The treatment can lead to the healing of chronic injuries and allow patients to live a fully normal life.
Researchers at MD Anderson Cancer Center have discovered that adding copper-loaded agents to radiotherapy can overcome radioresistance in preclinical models of thoracic cancer. A novel blood-based biomarker, OSMR, has also been identified in patients with acute myeloid leukemia (AML), which shows prognostic potential and can help ident...
A new study found that mesenchymal stem cell-derived extracellular vesicles significantly enhance survival and facilitate substantial peripheral blood recovery in mice exposed to high-dose irradiation. The treatment promoted hematopoietic recovery, with increases in red blood cell, platelet, white blood cell, and hemoglobin levels.
A UCLA study validates the predictive power of PROSTOX, a genetic test that uses microRNAs to identify patients at higher risk of developing long-lasting urinary side effects from radiation therapy. The test helps doctors and patients choose safer treatment options, reducing the burden of long-term complications.
Researchers found that combining imipridones with radiation therapy and temozolomide slowed glioblastoma growth and prolonged survival in mice. The treatment also boosted immune responses and suppressed MGMT protein expression, making it more effective.
The new Keck Medicine of USC – Newport Beach Radiation Oncology and Imaging Center offers biology-guided radiation therapy, using up-to-the-minute signals to track and treat cancer cells in real time. The center is equipped with state-of-the-art technology and will be the first in Orange County to provide this treatment option.
A study published in Plastic and Reconstructive Surgery reports that breast-conserving therapy, including radiation therapy, leads to progressive breast volume loss over time. Women with larger breasts experience greater total breast shrinkage, highlighting the need to discuss long-term changes in breast volume with patients.
Researchers at UT Health San Antonio have discovered a way to delay or even block recurrence of the deadliest brain cancer after radiation by targeting senescent cells with experimental 'senolytic' drugs. This approach shows promise in preventing tumor growth and improving patient survival.
Researchers aim to transform rectal cancer into a disease treatable with radiation therapy, avoiding long-term surgery side effects. Papaverine is investigated as a sensitizer that boosts oxygen content in tumor cells, allowing for maximal tumor destruction.
A natural citrus oil, when combined with a lipid formulation, may effectively relieve dry mouth in cancer patients. The new formula has demonstrated improved solubility and bioavailability compared to pure limonene.
A new editorial highlights a growing concern in cancer care: radiotherapy may leave behind residual disease that can lead to worse long-term outcomes. Studies have shown that patients with residual disease are more likely to experience cancer recurrence and shorter survival, emphasizing the need for regular biopsy-based tests.
A new study confirms that a shorter, higher-dose-per-day radiation course is as effective as conventional radiotherapy for treating early-stage prostate cancer without increasing side effects. The study found similar cancer control rates and fewer gastrointestinal issues with the new approach.
Researchers have uncovered a key mechanism involving Intermolecular Coulombic Decay (ICD) in aqueous environments initiated by heavy-ion irradiation, providing insights into the effectiveness of such irradiation. This process significantly increases the biological effectiveness of heavy-ion therapy.
The NRG Oncology GOG-0263 phase III clinical trial found that adding cisplatin-based chemotherapy to adjuvant radiotherapy following radical hysterectomy did not improve outcomes and led to increased toxicity. Radiotherapy alone remains the standard of care for early-stage, intermediate-risk cervical cancer.
Researchers found that the current standard monitoring time of one-and-a-half to two months following surgery is too short to accurately identify recurrence and inform treatment decisions. Monitoring PSA levels for at least three months can avoid overtreatment and mislabel patients as having recurred.
A team of researchers from Chiba University has developed a novel radioactive drug that targets and treats metastatic melanoma. The treatment utilizes astatine-211 labeled peptide analog, which shows high accumulation in tumors, rapid clearance from non-target organs, and significant tumor suppression.